Exiqon As (EXQNF) 2.6700 $EXQNF
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
PR Newswire - Thu Jun 23, 4:45AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QGEN: 26.84 (+0.23)
QIAGEN Changes Offer Conditions for Acquisition of Shares in Exiqon A/S
PR Newswire - Wed Jun 08, 9:13AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its decision to change the offer conditions for the acquisition of shares in Exiqon A/S, reducing the threshold from 90% to 89.20%. All other terms and conditions remain unchanged. In line with the Danish Takeover Order, which requires the extension of an offer period in case of changing offer terms and conditions, QIAGEN N.V. is further extending the offer period, which will now expire on 22 June 2016 at 23:59 (CET).
QGEN: 26.84 (+0.23)
QIAGEN Announces Second Offer Extension for the Acquisition of Shares in Exiqon A/S
PR Newswire - Fri Jun 03, 8:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash amount of DKK 18 for each share held in Exiqon A/S. This Offer Period had been extended on 19 May 2016, its terms and conditions remained unchanged. In accordance with the Offer, the extended Offer Period expired yesterday on 2 June 2016 at 23.59 (CET).
QGEN: 26.84 (+0.23)
QIAGEN Extends Tender Offer Period for Acquisition of Exiqon A/S
PR Newswire - Thu May 19, 9:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).
QGEN: 26.84 (+0.23)
QIAGEN Publishes Offer Document in Connection with the Conditional Voluntary Takeover Offer for the Shares in Exiqon A/S
PR Newswire - Tue Apr 19, 1:50AM CDT
QIAGEN N.V. ("NASDAQ: QGEN; Frankfurt Prime Standard: QIA"
announced on 29 March 2016 that QIAGEN N.V had decided to make a conditional, voluntary public tender offer for the shares of Exiqon A/S in which the shareholders of Exiqon are offered a cash amount of DKK 18 for each share they hold in Exiqon A/S (the "Offer" .
QGEN: 26.84 (+0.23)
QIAGEN to Submit Conditional Voluntary Takeover Offer for Shares of Exiqon A/S
PR Newswire - Tue Mar 29, 3:09PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it has decided to submit a conditional voluntary takeover offer to the shareholders of Exiqon A/S (NASDAQ OMX Copenhagen: EXQ) to purchase all shares in Exiqon. The acquisition is expected to expand QIAGEN's leadership position in Sample to Insight solutions for RNA analysis. This announcement is made in accordance with section 4 of the Danish Executive Order no. 562 of 2 June 2014 on takeover bids ("Executive Order on Takeover Bids" .
QGEN: 26.84 (+0.23)
200 Most Diversified Medical Devices/Technology/Supplies Companies Globally
M2 - Tue Oct 20, 6:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx7zxr/global_most) has announced the addition of the "Global Most Diversified Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 Most Diversified medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information, and stock market analysis. The global medical device sector is a highly diversified and export-oriented industry that manufactures medical equipments as well as supplies. The purchasers for the same include hospitals, physician's offices, laboratories, clinics as well as patients (through direct purchases). The sector is populated with companies driven by product innovation. The industry is able to draw on world-class innovative research being conducted in global universities, research institutes, and hospitals, some of which has been spun-off into global medical device companies. Big, highly diversified medical technology companies are tapping into health-care spending spikes in emerging countries. That's in contrast to a U.S. market for medical devices that is mature and slow growing. Emerging market countries have large, aging populations and rising incomes, which equates to 15 percent revenue growth for medical technology companies from those countries. The medical devices/technology sector has become increasingly dominated by larger, diversified companies such as Medtronic, Johnson & Johnson, Boston Scientific Corporation, St. Jude Medical, Guidant Corporation, Stryker Corporation, Zimmer Medical Holdings, Vasomedical, Inc., Integra LifeSciences Holdings Corporation, and many more. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the Most Diversified companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Highlights - Leading 200 Global Most Diversified medical devices/technology/supplies companies covered - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Most Diversified medical devices/technology/supplies companies - International presence of Global Most Diversified medical devices/technology/supplies companies - Key R&D activities by Global Most Diversified medical devices/technology/supplies companies Sample list of company names included in this industry report: - 3D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/lx...lobal_most
ATEC: 0.41 (+0.01), GBSNU: 16.22 (-0.28), MZOR: 23.53 (+0.16), FEIC: 106.56 (-0.04), BSX: 24.00 (-0.14), JNJ: 124.50 (+0.64), ZLTQ: 34.50 (+0.10), IARTV: 65.00 (-37.45), STJ: 83.45 (-0.08), BVX: 2.60 (unch), SYK: 114.85 (+0.03)
Global In-Situ Hybridization Market 2015 - Analysis and Forecast to 2019 for the $681 Million Market with Abbott, F. Hoffmann-La Roche, Affymetrix, Thermo Fisher Scientific & Agilent Technologies Dominating
PR Newswire Europe - Tue Sep 22, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nlp5vm/insitu [http://www.researchandmarkets.com/research/nlp5vm/insitu]) has announced the addition of the "In-Situ Hybridization Market by Type( DNA,RNA), Application (Cancer Diagnosis, Cytology, Immunology), End User (Hospitals, Pharma & Biotech, Research Labs) & by Geography - Analysis and Forecast to 2019" [http://www.researchandmarkets.com/research/nlp5vm/insitu] report to their offering.
A: 46.83 (-0.26), AFFX: 14.01 (+0.02)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 0.41 (+0.01), GBSNU: 16.22 (-0.28), MZOR: 23.53 (+0.16), FEIC: 106.56 (-0.04), ZLTQ: 34.50 (+0.10), IART: 84.60 (-0.07), BVX: 2.60 (unch)
qPCR and dPCR Instrumentation Market: Educational/Research, Testing Laboratories, Pharmaceuticals - Global Strategic Business Report
M2 - Tue Apr 14, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tg6qrs/qpcr_and_dpcr) has announced the addition of the "qPCR and dPCR Instrumentation - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Thousands by the following Product Segments: qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction). Also, the report analyzes the following End-Uses: Educational/Research, Testing Laboratories, Pharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a four-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 41 companies including many key and niche players such as: - Agilent Technologies, Inc. (US) - Becton, Dickinson and Company (US) - BioFire Diagnostics, Inc. (US) - Bio-Rad Laboratories, Inc. (US) - Cepheid (US) - Eppendorf AG (Germany) - Exiqon A/S (Denmark) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fluidigm Corporation (US) - Illumina, Inc. (US) - Promega Corporation (US) - RainDance Technologies, Inc. (US) - QIAGEN N.V. (Netherlands) - Takara Bio, Inc. (Japan) - Thermo Fisher Scientific Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS, MARKET TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 41 (including Divisions/Subsidiaries (44) - The United States (26) - Canada (1) - Japan (1) - Europe (15) - Germany (5) - The United Kingdom (2) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/tg...r_and_dpcr
FLDM: 10.72 (+0.27), A: 46.83 (-0.26), CPHD: 36.65 (-0.15), ILMN: 165.66 (+0.61), QGEN: 26.84 (+0.23)
Transgenomic Expands License Agreement with Exiqon to Support Global Commercialization of Its Multiplexed ICE COLD-PCR for Cancer Liquid Biopsies
BusinessWire - Wed Mar 11, 6:15AM CDT
Transgenomic, Inc. (NASDAQ:TBIO), today announced that it has signed an amended license agreement with Exiqon A/S for the expansion of rights to their proprietary Locked Nucleic Acid (LNA(TM)) oligonucleotides, which offer dramatically improved sensitivity and specificity compared to traditional DNA chemistries. The amended agreement provides Transgenomic with access to LNA oligos for use with all of the company's proprietary ultra-high sensitivity mutation enrichment technologies, including its Multiplexed ICE COLD-PCR(TM) (MX-ICP). It covers Transgenomic's commercial worldwide use of LNA oligos for analysis of all cancer genes on all platforms, including cutting edge approaches such as next-generation sequencing (NGS).
TBIO: 0.36 (-0.02)
qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets) Report 2013-2018
M2 - Tue Nov 18, 9:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/tv8xlw/qpcr_and_dpcr) has announced the addition of the "qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets)" report to their offering. Real time qPCR is considered the gold standard for accurate, sensitive, and fast quantification of nucleic acid sequences. PCR technologies, specifically qPCR (quantitative PCR) and digital PCR (dPCR) show significant promise for growth. qPCR is mainly a workhorse in the research laboratory, while dPCR is helping to push the potential for diagnostic applications due to its sensitivity, precision, robustness and reproducibility. qPCR has been established for a broad range of applications including gene expression, genotyping, pathogen detection, DNA methylation analysis. qPCR is increasingly being used in the medical diagnostic arena for diagnosis of bacterial disease, detection of antibiotic resistance, diagnosis of infectious disease and quantification of bacterial load. It is also used to detect genetic abnormalities and cancer mutations. qPCR-based diagnostic tests are expected to expand in the coming years. dPCR provides absolute measurement of copies and would seem to be the next logical step in PCR evolution. dPCR partitions the sample and reaction components into hundreds or thousands of reaction chambers to count the presence or absence of molecules. It provides greatly improved sensitivity in the detection of rare mutations and sequences. This technology will become increasingly important in the clinical application of PCR. Segments Include: - Clinical Market for qPCR - Research Market for qPCR - Clinical Market for dPCR - Research Market for dPCR - qPCR Instruments - qPCR Reagents - qPCR Software and Services - dPCR Instruments - dPCR Reagents - dPCR Software and Services Some of the market drivers influencing participation: - A global aging population - An increase in the number of population affected by chronic medical conditions - Advancements in gene detection and technologies - The increasing role of diagnostics in home health and remote patient care - Personalized medicine - Advancements next generation sequencing and multi-gene approaches Challenges facing those in the market, including: - Development financial, time investment risk - Uncertain regulatory environment - Cost to patient may limit accessibility in many regions - Economic uncertainty: patients are likely to decline advanced testing in times of hardship - New technologies more difficult to develop Some of the issues and trends affecting this market are: - BRIC Involvement - qPCR and Robotics - Lab-on-a-Chip Devices - Molecular Testing Reimbursement Companies profiles in this report include: - Abbott Laboratories - Affymetrix - Aglient Technologies - Analytik Jena AG - Becton Dickinson - BioFire Diagnostics - bioMerieux - Bio-Rad Laboratories - Cephid - Denville Scientific - Eppendorf AG - Exiqon A/S - Fluidigm - Illumina - Kyratec - Life Techologies - Promega - Qiagen - RainDance Technologies - Roche - Sacace Biotechnologies - Takaro Bio - Thermo Fisher Scientific - WaferGen Biosystems For more information visit http://www.researchandmarkets.com/research/tv...r_and_dpcr
ABT: 44.82 (+0.01)
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
PR Newswire - Thu Jun 23, 4:45AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QGEN: 26.84 (+0.23)
QIAGEN Changes Offer Conditions for Acquisition of Shares in Exiqon A/S
PR Newswire - Wed Jun 08, 9:13AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its decision to change the offer conditions for the acquisition of shares in Exiqon A/S, reducing the threshold from 90% to 89.20%. All other terms and conditions remain unchanged. In line with the Danish Takeover Order, which requires the extension of an offer period in case of changing offer terms and conditions, QIAGEN N.V. is further extending the offer period, which will now expire on 22 June 2016 at 23:59 (CET).
QGEN: 26.84 (+0.23)
QIAGEN Announces Second Offer Extension for the Acquisition of Shares in Exiqon A/S
PR Newswire - Fri Jun 03, 8:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash amount of DKK 18 for each share held in Exiqon A/S. This Offer Period had been extended on 19 May 2016, its terms and conditions remained unchanged. In accordance with the Offer, the extended Offer Period expired yesterday on 2 June 2016 at 23.59 (CET).
QGEN: 26.84 (+0.23)
QIAGEN Extends Tender Offer Period for Acquisition of Exiqon A/S
PR Newswire - Thu May 19, 9:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).
QGEN: 26.84 (+0.23)
QIAGEN Publishes Offer Document in Connection with the Conditional Voluntary Takeover Offer for the Shares in Exiqon A/S
PR Newswire - Tue Apr 19, 1:50AM CDT
QIAGEN N.V. ("NASDAQ: QGEN; Frankfurt Prime Standard: QIA"
announced on 29 March 2016 that QIAGEN N.V had decided to make a conditional, voluntary public tender offer for the shares of Exiqon A/S in which the shareholders of Exiqon are offered a cash amount of DKK 18 for each share they hold in Exiqon A/S (the "Offer" . QGEN: 26.84 (+0.23)
QIAGEN to Submit Conditional Voluntary Takeover Offer for Shares of Exiqon A/S
PR Newswire - Tue Mar 29, 3:09PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it has decided to submit a conditional voluntary takeover offer to the shareholders of Exiqon A/S (NASDAQ OMX Copenhagen: EXQ) to purchase all shares in Exiqon. The acquisition is expected to expand QIAGEN's leadership position in Sample to Insight solutions for RNA analysis. This announcement is made in accordance with section 4 of the Danish Executive Order no. 562 of 2 June 2014 on takeover bids ("Executive Order on Takeover Bids"
. QGEN: 26.84 (+0.23)
200 Most Diversified Medical Devices/Technology/Supplies Companies Globally
M2 - Tue Oct 20, 6:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lx7zxr/global_most) has announced the addition of the "Global Most Diversified Medical Devices/Technology/Supplies 200 " report to their offering. The newly launched report identifies 200 Most Diversified medical devices/technology/supplies companies globally and covers various aspects of these 200 companies including news, financial/non-financial information, and stock market analysis. The global medical device sector is a highly diversified and export-oriented industry that manufactures medical equipments as well as supplies. The purchasers for the same include hospitals, physician's offices, laboratories, clinics as well as patients (through direct purchases). The sector is populated with companies driven by product innovation. The industry is able to draw on world-class innovative research being conducted in global universities, research institutes, and hospitals, some of which has been spun-off into global medical device companies. Big, highly diversified medical technology companies are tapping into health-care spending spikes in emerging countries. That's in contrast to a U.S. market for medical devices that is mature and slow growing. Emerging market countries have large, aging populations and rising incomes, which equates to 15 percent revenue growth for medical technology companies from those countries. The medical devices/technology sector has become increasingly dominated by larger, diversified companies such as Medtronic, Johnson & Johnson, Boston Scientific Corporation, St. Jude Medical, Guidant Corporation, Stryker Corporation, Zimmer Medical Holdings, Vasomedical, Inc., Integra LifeSciences Holdings Corporation, and many more. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the Most Diversified companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Highlights - Leading 200 Global Most Diversified medical devices/technology/supplies companies covered - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of Global Most Diversified medical devices/technology/supplies companies - International presence of Global Most Diversified medical devices/technology/supplies companies - Key R&D activities by Global Most Diversified medical devices/technology/supplies companies Sample list of company names included in this industry report: - 3D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/lx...lobal_most
ATEC: 0.41 (+0.01), GBSNU: 16.22 (-0.28), MZOR: 23.53 (+0.16), FEIC: 106.56 (-0.04), BSX: 24.00 (-0.14), JNJ: 124.50 (+0.64), ZLTQ: 34.50 (+0.10), IARTV: 65.00 (-37.45), STJ: 83.45 (-0.08), BVX: 2.60 (unch), SYK: 114.85 (+0.03)
Global In-Situ Hybridization Market 2015 - Analysis and Forecast to 2019 for the $681 Million Market with Abbott, F. Hoffmann-La Roche, Affymetrix, Thermo Fisher Scientific & Agilent Technologies Dominating
PR Newswire Europe - Tue Sep 22, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nlp5vm/insitu [http://www.researchandmarkets.com/research/nlp5vm/insitu]) has announced the addition of the "In-Situ Hybridization Market by Type( DNA,RNA), Application (Cancer Diagnosis, Cytology, Immunology), End User (Hospitals, Pharma & Biotech, Research Labs) & by Geography - Analysis and Forecast to 2019" [http://www.researchandmarkets.com/research/nlp5vm/insitu] report to their offering.
A: 46.83 (-0.26), AFFX: 14.01 (+0.02)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 0.41 (+0.01), GBSNU: 16.22 (-0.28), MZOR: 23.53 (+0.16), FEIC: 106.56 (-0.04), ZLTQ: 34.50 (+0.10), IART: 84.60 (-0.07), BVX: 2.60 (unch)
qPCR and dPCR Instrumentation Market: Educational/Research, Testing Laboratories, Pharmaceuticals - Global Strategic Business Report
M2 - Tue Apr 14, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tg6qrs/qpcr_and_dpcr) has announced the addition of the "qPCR and dPCR Instrumentation - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for qPCR and dPCR Instrumentation in US$ Thousands by the following Product Segments: qPCR (quantitative Polymerase Chain Reaction), and dPCR (digital Polymerase Chain Reaction). Also, the report analyzes the following End-Uses: Educational/Research, Testing Laboratories, Pharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a four-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 41 companies including many key and niche players such as: - Agilent Technologies, Inc. (US) - Becton, Dickinson and Company (US) - BioFire Diagnostics, Inc. (US) - Bio-Rad Laboratories, Inc. (US) - Cepheid (US) - Eppendorf AG (Germany) - Exiqon A/S (Denmark) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fluidigm Corporation (US) - Illumina, Inc. (US) - Promega Corporation (US) - RainDance Technologies, Inc. (US) - QIAGEN N.V. (Netherlands) - Takara Bio, Inc. (Japan) - Thermo Fisher Scientific Inc. (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. GROWTH DRIVERS, MARKET TRENDS & ISSUES 3. COMPETITION 4. END-USE MARKET ANALYSIS 5. PRODUCT OVERVIEW 6. INSIGHT INTO GLOBAL SPENDING ON LIFE SCIENCES RESEARCH 7. PRODUCT INNOVATIONS/INTRODUCTIONS 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT GLOBAL PLAYERS 10. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 41 (including Divisions/Subsidiaries (44) - The United States (26) - Canada (1) - Japan (1) - Europe (15) - Germany (5) - The United Kingdom (2) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) For more information visit http://www.researchandmarkets.com/research/tg...r_and_dpcr
FLDM: 10.72 (+0.27), A: 46.83 (-0.26), CPHD: 36.65 (-0.15), ILMN: 165.66 (+0.61), QGEN: 26.84 (+0.23)
Transgenomic Expands License Agreement with Exiqon to Support Global Commercialization of Its Multiplexed ICE COLD-PCR for Cancer Liquid Biopsies
BusinessWire - Wed Mar 11, 6:15AM CDT
Transgenomic, Inc. (NASDAQ:TBIO), today announced that it has signed an amended license agreement with Exiqon A/S for the expansion of rights to their proprietary Locked Nucleic Acid (LNA(TM)) oligonucleotides, which offer dramatically improved sensitivity and specificity compared to traditional DNA chemistries. The amended agreement provides Transgenomic with access to LNA oligos for use with all of the company's proprietary ultra-high sensitivity mutation enrichment technologies, including its Multiplexed ICE COLD-PCR(TM) (MX-ICP). It covers Transgenomic's commercial worldwide use of LNA oligos for analysis of all cancer genes on all platforms, including cutting edge approaches such as next-generation sequencing (NGS).
TBIO: 0.36 (-0.02)
qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets) Report 2013-2018
M2 - Tue Nov 18, 9:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/tv8xlw/qpcr_and_dpcr) has announced the addition of the "qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets)" report to their offering. Real time qPCR is considered the gold standard for accurate, sensitive, and fast quantification of nucleic acid sequences. PCR technologies, specifically qPCR (quantitative PCR) and digital PCR (dPCR) show significant promise for growth. qPCR is mainly a workhorse in the research laboratory, while dPCR is helping to push the potential for diagnostic applications due to its sensitivity, precision, robustness and reproducibility. qPCR has been established for a broad range of applications including gene expression, genotyping, pathogen detection, DNA methylation analysis. qPCR is increasingly being used in the medical diagnostic arena for diagnosis of bacterial disease, detection of antibiotic resistance, diagnosis of infectious disease and quantification of bacterial load. It is also used to detect genetic abnormalities and cancer mutations. qPCR-based diagnostic tests are expected to expand in the coming years. dPCR provides absolute measurement of copies and would seem to be the next logical step in PCR evolution. dPCR partitions the sample and reaction components into hundreds or thousands of reaction chambers to count the presence or absence of molecules. It provides greatly improved sensitivity in the detection of rare mutations and sequences. This technology will become increasingly important in the clinical application of PCR. Segments Include: - Clinical Market for qPCR - Research Market for qPCR - Clinical Market for dPCR - Research Market for dPCR - qPCR Instruments - qPCR Reagents - qPCR Software and Services - dPCR Instruments - dPCR Reagents - dPCR Software and Services Some of the market drivers influencing participation: - A global aging population - An increase in the number of population affected by chronic medical conditions - Advancements in gene detection and technologies - The increasing role of diagnostics in home health and remote patient care - Personalized medicine - Advancements next generation sequencing and multi-gene approaches Challenges facing those in the market, including: - Development financial, time investment risk - Uncertain regulatory environment - Cost to patient may limit accessibility in many regions - Economic uncertainty: patients are likely to decline advanced testing in times of hardship - New technologies more difficult to develop Some of the issues and trends affecting this market are: - BRIC Involvement - qPCR and Robotics - Lab-on-a-Chip Devices - Molecular Testing Reimbursement Companies profiles in this report include: - Abbott Laboratories - Affymetrix - Aglient Technologies - Analytik Jena AG - Becton Dickinson - BioFire Diagnostics - bioMerieux - Bio-Rad Laboratories - Cephid - Denville Scientific - Eppendorf AG - Exiqon A/S - Fluidigm - Illumina - Kyratec - Life Techologies - Promega - Qiagen - RainDance Technologies - Roche - Sacace Biotechnologies - Takaro Bio - Thermo Fisher Scientific - WaferGen Biosystems For more information visit http://www.researchandmarkets.com/research/tv...r_and_dpcr
ABT: 44.82 (+0.01)
